Virtue Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $442K | Buy |
18,343
+1,529
| +9% | +$40K | 0.06% | 218 |
|
|
2026
Q1 | $467K | Buy |
16,814
+1,456
| +9% | +$38.8K | 0.07% | 197 |
|
|
2025
Q4 | $387K | Sell |
15,358
-67,938
| -82% | -$1.71M | 0.06% | 204 |
|
|
2025
Q3 | $1.08M | Buy |
83,296
+70,386
| +545% | +$1.74M | 0.17% | 99 |
|
|
2025
Q2 | $313K | Sell |
12,910
-12,022
| -48% | -$280K | 0.06% | 194 |
|
|
2025
Q1 | $632K | Buy |
24,932
+10,644
| +74% | +$279K | 0.07% | 219 |
|
|
2024
Q4 | $379K | Buy |
14,288
+1,179
| +9% | +$32K | 0.08% | 177 |
|
|
2024
Q3 | $379K | Sell |
13,109
-7,815
| -37% | -$228K | 0.08% | 179 |
|
|
2024
Q2 | $617K | Sell |
20,924
-2,088
| -9% | -$57.5K | 0.11% | 172 |
|
|
2024
Q1 | $601K | Sell |
23,012
-6,619
| -22% | -$184K | 0.11% | 175 |
|
|
2023
Q4 | $868K | Sell |
29,631
-6,352
| -18% | -$192K | 0.18% | 107 |
|
|
2023
Q3 | $1.31M | Hold |
35,983
| – | – | 0.22% | 82 |
|
|
2023
Q2 | $1.31M | Buy |
35,983
+3,524
| +11% | +$137K | 0.22% | 82 |
|
|
2023
Q1 | $1.25M | Sell |
32,459
-5,080
| -14% | -$219K | 0.21% | 81 |
|
|
2022
Q4 | $1.92M | Buy |
37,539
+20,009
| +114% | +$959K | 0.29% | 50 |
|
|
2022
Q3 | $767K | Sell |
17,530
-2,248
| -11% | -$109K | 0.12% | 79 |
|
|
2022
Q2 | $1.04M | Sell |
19,778
-18,996
| -49% | -$968K | 0.16% | 59 |
|
|
2022
Q1 | $2.01M | Buy |
38,774
+5,844
| +18% | +$303K | 0.32% | 64 |
|
|
2021
Q4 | $1.95M | Sell |
32,930
-1,345
| -4% | -$66.6K | 0.29% | 79 |
|
|
2021
Q3 | $1.47M | Buy |
34,275
+4,000
| +13% | +$177K | 0.26% | 98 |
|
|
2021
Q2 | $1.19M | Sell |
30,275
-4,506
| -13% | -$175K | 0.24% | 125 |
|
|
2021
Q1 | $1.26M | Buy |
34,781
+462
| +1% | +$16.4K | 0.3% | 99 |
|
|
2020
Q4 | $1.26M | Sell |
34,319
-6,262
| -15% | -$230K | 0.31% | 96 |
|
|
2020
Q3 | $1.41M | Sell |
40,581
-13,179
| -25% | -$462K | 0.35% | 81 |
|
|
2020
Q2 | $1.67M | Buy |
+53,760
| New | +$1.83M | 0.38% | 75 |
|
|
2020
Q1 | – | Sell |
-11,858
| Closed | -$441K | – | 160 |
|
|
2019
Q4 | $441K | Sell |
11,858
-35,003
| -75% | -$1.25M | 0.13% | 158 |
|
|
2019
Q3 | $1.6M | Sell |
46,861
-4,646
| -9% | -$169K | 0.53% | 60 |
|
|
2019
Q2 | $2.12M | Buy |
51,507
+41,709
| +426% | +$1.66M | 0.77% | 40 |
|
|
2019
Q1 | $395K | Sell |
9,798
-1,511
| -13% | -$60.5K | 0.14% | 58 |
|
|
2018
Q4 | $468K | Sell |
11,309
-78,741
| -87% | -$3.27M | 0.22% | 36 |
|
|
2018
Q3 | $3.77M | Buy |
90,050
+43,248
| +92% | +$1.66M | 0.8% | 39 |
|
|
2018
Q2 | $1.61M | Buy |
46,802
+2,968
| +7% | +$101K | 0.78% | 33 |
|
|
2018
Q1 | $1.53M | Buy |
43,834
+3,485
| +9% | +$120K | 0.81% | 12 |
|
|
2017
Q4 | $1.39M | Buy |
+40,349
| New | +$1.38M | 0.79% | 8 |
|
Other funds holding PFE
Virtue Capital Management's PFE Position: Q2 2026 in Review
Virtue Capital Management increased its Pfizer (PFE) stake by 9.1% in Q2 2026, buying an estimated $40K and bringing the position to 18,343 shares worth $442K. The position accounts for 0.06% of the portfolio, ranked #218.
Virtue Capital Management first reported a position in PFE in Q4 2017 and has held it in 34 quarters since. The position peaked at $3.77M in Q3 2018. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Virtue Capital Management held 18,343 shares of Pfizer worth $442K as of Q2 2026.
- Virtue Capital Management bought 1,529 Pfizer shares in Q2 2026, an estimated $40K.
- Pfizer made up 0.06% of Virtue Capital Management's portfolio in Q2 2026, its #218 holding.
- Virtue Capital Management first reported a position in Pfizer in Q4 2017 and has held it in 34 quarters since.
- Virtue Capital Management's Pfizer position peaked at $3.77M in Q3 2018.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Virtue Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.